Ryan J. Sullivan, MD, associate director of Melanoma at the Massachusetts General Hospital, discusses the significance of the BRAF/MEK combination dabrafenib (Tafinlar) and trametinib (Mekinist), which was the first BRAF/MEK inhibitor regimen to be approved by the FDA for the treatment of patients with BRAF V600E–positive stage III melanoma following complete resection.
Video Reports
First-in-Human Trial for Tebentafusp In Advanced Melanoma Shows Promising Safety Profile
Findings from the first-in-human trial evaluating tebentafusp (IMCgp100), a TCR–CD3 bispecific, in patients with advanced melanoma show tebentafusp not only working but showing a favorable safety profile, according to Alexander N. Shoushtari, MD.
Dr. Atkins on Long-Term Outcomes of the CheckMate-204 Trial in Melanoma
Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, discusses long-term outcomes of the phase II CheckMate-204 trial in metastatic melanoma.
ESMO 2019: Dr. Hamid Discusses Exciting Immunotherapy Data in Melanoma
Omid Hamid, MD, director of Research and Immuno-Oncology at The Angeles Clinic, discusses exciting immunotherapy data presented at the 2019 ESMO Congress.